ETHY-001 targets the causal pathogenic mechanism underlying both conditions –– Patient-friendly subcutaneous administration with half-life ...
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could ...
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...
Graves disease (GD)-associated hyperthyroidism is an autoimmune disorder characterized by the presence of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), leading to ...
For assay validation and LD analysis, 86 control samples from the UK were genotyped. In order to limit the amount of genotyping, save DNA resources and decrease reagent expenditure, a two-staged ...
Kissei Pharmaceutical Co. Ltd. has described 3,4-dihydroquinolin-2(1H)-one compounds acting as thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the ...
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company developing precision therapies for thyroid diseases with high unmet need, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results